Related Experiment Video
Updated: Apr 8, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling
E Flashner-Abramson1, S Klein1, G Mullin1
1Department of Biological Chemistry, Unit of Cellular Signaling, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Abstract:
It is well known that specific signal transduction inhibitors rarely suffice as anti-cancer agents. In most cases, tumors possess primary drug resistance due to their inherent heterogeneity, or acquire drug resistance due to genomic instability and acquisition of mutations. Here we expand our previous study of the novel compound, NT157, and show that it acts as a dual-targeting agent that invokes the blockage of two signal transduction pathways that are central to the development and maintenance of multiple human cancers. We show that NT157 targets not only IGF1R-IRS1/2, as previously reported, but also the Stat3 signaling pathway and demonstrates remarkable anti-cancer characteristics in A375 human melanoma cells and in a metastatic melanoma model in mice.
Insights
The novel compound NT157 targets two key cancer pathways, IGF1R-IRS1/2 and Stat3 signaling. This dual-targeting approach shows significant anti-cancer effects in melanoma models.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer drug resistance is a major challenge, often stemming from tumor heterogeneity and genomic instability.
- Targeting single signal transduction pathways frequently proves insufficient for effective cancer treatment.
Purpose of the Study:
- To investigate the novel compound NT157 as a dual-targeting anti-cancer agent.
- To elucidate the specific signal transduction pathways inhibited by NT157.
Main Methods:
- Preclinical evaluation of NT157 in A375 human melanoma cells.
- Assessment of NT157 efficacy in a murine model of metastatic melanoma.
Main Results:
- NT157 was confirmed to target the Insulin-like Growth Factor 1 Receptor (IGF1R)-Insulin Receptor Substrate (IRS1/2) pathway.
- NT157 also effectively inhibits the Signal Transducer and Activator of Transcription 3 (Stat3) signaling pathway.
- Demonstrated significant anti-cancer activity in both cell lines and animal models.
Conclusions:
- NT157 exhibits dual-targeting capabilities against critical cancer pathways.
- This dual-inhibition strategy holds promise for overcoming drug resistance and treating advanced melanoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy